Biohaven Pharmaceutical Holding Company Ltd. re-affirmed sales guidance for the full year 2022. For the year, the company expected net product sales of $825 million to $900 million.
Biohaven Pharmaceutical Holding Company Ltd.
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.81 USD | +4.25% | +4.94% | -77.07% |
05-31 | Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing | MT |
05-15 | Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing | MT |
1st Jan change | Capi. | |
---|---|---|
-77.07% | 541M | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- BHVN Stock
- News Biohaven Pharmaceutical Holding Company Ltd.
- Biohaven Pharmaceutical Holding Company Ltd. Re-Affirms Sales Guidance for the Full Year 2022